| Literature DB >> 33913412 |
N Cereceda-Monteoliva1, Y Devabalan1, H Lorenz1, J C Magill1, S Unadkat1, C Rennie1.
Abstract
BACKGROUND: The impact of coronavirus disease 2019 on healthcare has led to rapid changes in otolaryngology service provisions. As such, new standard operating procedures for the management of suspected tonsillitis or quinsy were implemented in our centre.Entities:
Keywords: Coronavirus; Otolaryngology; Pandemics; Peritonsillar Abscess; Quality Improvement; Tonsillitis
Year: 2021 PMID: 33913412 PMCID: PMC8220009 DOI: 10.1017/S0022215121001213
Source DB: PubMed Journal: J Laryngol Otol ISSN: 0022-2151 Impact factor: 1.469
Demographic data
| Parameter | Group 1* | Group 2† | |
|---|---|---|---|
| Total referrals ( | 107 | 49 | |
| Quinsy referrals ( | 48 (44.9) | 30 (61.2) | 0.042‡ |
| Gender ( | |||
| – Male | 58 (54.2) | 30 (61.2) | 0.412 |
| – Female | 49 (45.8) | 19 (38.8) | 0.412 |
| Age (mean (range); years) | 31 (17–86) | 35 (17–79) | 0.117 |
*Pre- and †post-implementation of new standard operating procedures. ‡Indicates statistical significance
Initial treatment measures
| Parameter | Group 1* | Group 2† | |
|---|---|---|---|
| Time in emergency department (mean (range); minutes) | 293 (43–1557) | 276 (42–1468) | 0.576 |
| Examination ( | |||
| – Oronasal | 107 (100) | 49 (100) | – |
| – Nasendoscopy | 36 (33.6) | 7 (14.3) | 0.012‡ |
| Intravenous therapy ( | |||
| – None | 10 (9.3) | 1 (2.0) | 0.098 |
| – Antibiotic only | 14 (13.1) | 23 (46.9) | <0.001‡ |
| – Antibiotics & corticosteroids | 83 (77.6) | 25 (51.0) | 0.001‡ |
| Drainage ( | |||
| – None attempted | 62 (57.9) | 17 (34.7) | 0.007 |
| – Needle aspiration of pus | 33 (30.8) | 15 (30.6) | 0.977 |
| – Dry needle aspirate | 10 (9.3) | 13 (26.5) | 0.005‡ |
| – Incision & drainage | 2 (1.9) | 4 (8.2) | 0.058 |
| Covid-19 swab on admission ( | 0 (0) | 11 (22.4) | – |
*Pre- and †post-implementation of new standard operating procedures. ‡Indicates statistical significance. Covid-19 = coronavirus disease 2019
Fig. 1.Intravenous (IV) treatment strategies for groups 1 and 2 (pre- and post-implementation of new standard operating procedures, respectively) (*p < 0.05).
Fig. 2.Procedures performed for quinsy drainage under local anaesthetic, for groups 1 and 2 (pre- and post-implementation of new standard operating procedures, respectively) (*p < 0.05).
Outcome data
| Parameter | Group 1* | Group 2† | |
|---|---|---|---|
| Mortalities ( | 0 (0) | 0 (0) | – |
| Admissions ( | 60 (56.1) | 10 (20.4) | <0.001‡ |
| Length of hospital stay (mean (range); days) | 1.13 (1–3) | 1.5 (1–3) | 0.029‡ |
| Follow up ( | |||
| – None, as routine | 86 (80.4) | 37 (78.7) | 0.490 |
| – Virtual | 5 (4.7) | 8 (16.3) | 0.015 |
| – Face-to-face | 16 (15.0) | 4 (8.2) | 0.031‡ |
| Re-presentation ( | |||
| – None | 96 (89.7) | 42 (85.7) | 0.467 |
| – Before day 10 | 8 (7.5) | 6 (12.2) | 0.333 |
| – On or after day 10 | 3 (2.8) | 1 (2.0) | 0.588 |
| Positive Covid-19 status ( | 0 (0) | – |
*Pre- and †post-implementation of new standard operating procedures. ‡Indicates statistical significance. Covid-19 = coronavirus disease 2019
| Management of peritonsillar abscess* |
|---|
| ATLS/ALS care & specialist ENT assessment where possible |
| Manage patient in short stay or out-patient clinic setting |
| Attempt aspiration or I&D |
| IV access, fluid resuscitation |
| IV dexamethasone (risks should be discussed with patient) |
| IV penicillin & metronidazole |
| Analgesia such as paracetamol, ibuprofen, codeine (dissolvable if appropriate) |
| Reassess after 1–2 hours; discharge if able to swallow water, with oral antibiotics & analgesia |
| Safety netting advice |
| Emergency clinic telephone follow up |
*Adapted from ENT UK guidelines. Covid-19 = coronavirus disease 2019; ATLS = advanced trauma life support; ALS = advanced life support; I&D = incision and drainage; IV = intravenous